Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market indomethacin extended release capsules used in treating painful and inflammatory conditions such as arthritis.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 75 mg, it said in a BSE filing.
It will manufacture the drug at the Moraiya facility in Ahmedabad.
Zydus Cadila said it has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of the company's listed entity Cadila Healthcare were trading 2.70 per cent down at Rs 461.50 per scrip on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
